Guggenheim analyst Debjit Chattopadhyay initiated coverage of NewAmsterdam Pharma with a Buy rating and $30 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NAMS:
- NewAmsterdam Pharma initiated with an Overweight at Piper Sandler
- NewAmsterdam Pharma appoints William Lewis as chair of board
- NewAmsterdam Pharma expects cash to support operations through 2026
- NewAmsterdam Pharma announces upcoming milestones
- NewAmsterdam Pharma Announces 2024 Strategic Priorities